Point-of-Care Microfluidics and Lab-on-a-Chip

Abbott Laboratories, Roche Diagnostics, Danaher Life Science and bioMerieux are among the companies active in this field. Abbott’s i-STAT analyzers use disposable cartridges for near-patient testing, while Danaher’s Cepheid business offers cartridge-based PCR systems. Bio-Rad Laboratories contributes expertise in droplet-based digital PCR, though its platforms are primarily laboratory tools.

Genspeed Biotech GmbH is the startup identified in the available facts, with 4 documents in the defined window. Associated researchers have evaluated rapid point-of-care detection of complement activation in critically ill patients. Related work explores foil-based microfluidic chips with electrochemical or chemiluminescent readouts, but the available information is not enough to rank startup prospects.

The Chinese Academy of Sciences CAS has 417 documents in the defined window, followed by Zhejiang University with 158 and Tsinghua University with 147. Shanghai JiaoTong University has 136 and recently reported a centrifugal microfluidic CRISPR platform for multiplex respiratory-pathogen testing. These figures identify prominent research contributors, not a measure of research quality.

The facts list $341,757,252 in grants since 2020 and $1,710,138,033 across 24 funding rounds. These are aggregate funding figures associated with the topic data, rather than verified totals for individual products or companies. The figures therefore indicate recorded funding activity but should not be read as funding dedicated exclusively to point-of-care microfluidic development.

The French National Center for Scientific Research is listed with 9 patents, followed by Health Sciences with 8 and Nicoya Lifesciences Inc. with 7. CAS Shenzhen Institutes of Advanced Technology, BOE Technology Group, ABS Global, Toppan Corporation and INTEGRA Biosciences AG each have 6 listed patents. These counts reflect the patent-holder data provided for this topic.

Patent activity declined 54.6% in the last 12 months compared with the previous 12 months, while publications increased 9% over that period. The contrast suggests recent research activity has not been matched by patent growth. These are changes in activity over the defined comparison window, not a forecast of future filings or commercial adoption.

Recent developments include Shanghai JiaoTong University’s August 2026 centrifugal CRISPR platform for multiplex respiratory-pathogen testing and a September 2026 paper-based chip combining amplification with smartphone readout for urinary biomarker quantification. Other recent work integrated a nanozyme probe into centrifugal microfluidics for immunoassay and used acoustofluidics for sample-to-answer extracellular-vesicle analysis.

Emerging terms include biosensing techniques, point-of-care systems, limit of detection, isolation and purification, rapid diagnostic tests, and nucleic acid amplification techniques. Recent studies also combine centrifugal microfluidics with CRISPR, use paper chips with smartphone readout, and apply acoustofluidic separation to extracellular-vesicle analysis. The direction is toward integrating sample handling, detection and result interpretation in compact workflows.

The listed applications include infectious disease testing, oncology diagnostics, chronic disease monitoring, and reproductive and maternal health. Infectious disease work includes pathogen screening, while oncology research includes biomarker and liquid-biopsy approaches. Chronic disease monitoring can use markers such as albumin, creatinine or glucose; the facts also identify reproductive and maternal health as an application area.